These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 36925912)

  • 1. Breast cancer subtype and clinical characteristics in women from Peru.
    Zavala VA; Casavilca-Zambrano S; Navarro-Vásquez J; Tamayo LI; Castañeda CA; Valencia G; Morante Z; Calderón M; Abugattas JE; Gómez HL; Fuentes HA; Liendo-Picoaga R; Cotrina JM; Neciosup SP; Roque K; Vásquez J; Mas L; Gálvez-Nino M; Fejerman L; Vidaurre T
    Front Oncol; 2023; 13():938042. PubMed ID: 36925912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women.
    Marker KM; Zavala VA; Vidaurre T; Lott PC; Vásquez JN; Casavilca-Zambrano S; Calderón M; Abugattas JE; Gómez HL; Fuentes HA; Picoaga RL; Cotrina JM; Neciosup SP; Castañeda CA; Morante Z; Valencia F; Torres J; Echeverry M; Bohórquez ME; Polanco-Echeverry G; Estrada-Florez AP; Serrano-Gómez SJ; Carmona-Valencia JA; Alvarado-Cabrero I; Sanabria-Salas MC; Velez A; Donado J; Song S; Cherry D; Tamayo LI; Huntsman S; Hu D; Ruiz-Cordero R; Balassanian R; Ziv E; Zabaleta J; Carvajal-Carmona L; Fejerman L;
    Cancer Res; 2020 May; 80(9):1893-1901. PubMed ID: 32245796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women.
    Zavala VA; Casavilca-Zambrano S; Navarro-Vásquez J; Castañeda CA; Valencia G; Morante Z; Calderón M; Abugattas JE; Gómez H; Fuentes HA; Liendo-Picoaga R; Cotrina JM; Monge C; Neciosup SP; Huntsman S; Hu D; Sánchez SE; Williams MA; Núñez-Marrero A; Godoy L; Hechmer A; Olshen AB; Dutil J; Ziv E; Zabaleta J; Gelaye B; Vásquez J; Gálvez-Nino M; Enriquez-Vera D; Vidaurre T; Fejerman L
    Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1602-1609. PubMed ID: 35654312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 status and disparities in luminal breast cancers.
    Holowatyj AN; Ruterbusch JJ; Ratnam M; Gorski DH; Cote ML
    Cancer Med; 2016 Aug; 5(8):2109-16. PubMed ID: 27250116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women.
    Rojas-Lima E; Gamboa-Loira B; Cebrián ME; Rothenberg SJ; López-Carrillo L
    Breast Cancer Res Treat; 2020 Apr; 180(3):791-800. PubMed ID: 32086656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study.
    Song N; Choi JY; Sung H; Chung S; Song M; Park SK; Han W; Lee JW; Kim MK; Yoo KY; Ahn SH; Noh DY; Kang D
    Int J Cancer; 2014 Aug; 135(3):669-81. PubMed ID: 24916400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study.
    Brouckaert O; Rudolph A; Laenen A; Keeman R; Bolla MK; Wang Q; Soubry A; Wildiers H; Andrulis IL; Arndt V; Beckmann MW; Benitez J; Blomqvist C; Bojesen SE; Brauch H; Brennan P; Brenner H; Chenevix-Trench G; Choi JY; Cornelissen S; Couch FJ; Cox A; Cross SS; Czene K; Eriksson M; Fasching PA; Figueroa J; Flyger H; Giles GG; González-Neira A; Guénel P; Hall P; Hollestelle A; Hopper JL; Ito H; Jones M; Kang D; ; Knight JA; Kosma VM; Li J; Lindblom A; Lilyquist J; Lophatananon A; Mannermaa A; Manoukian S; Margolin S; Matsuo K; Muir K; Nevanlinna H; Peterlongo P; Pylkäs K; Saajrang S; Seynaeve C; Shen CY; Shu XO; Southey MC; Swerdlow A; Teo SH; Tollenaar RAEM; Truong T; Tseng CC; van den Broek AJ; van Deurzen CHM; Winqvist R; Wu AH; Yip CH; Yu JC; Zheng W; Milne RL; Pharoah PDP; Easton DF; Schmidt MK; Garcia-Closas M; Chang-Claude J; Lambrechts D; Neven P
    Breast Cancer Res; 2017 Nov; 19(1):119. PubMed ID: 29116004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial/ethnic differences in the utilization of chemotherapy among stage I-III breast cancer patients, stratified by subtype: Findings from ten National Program of Cancer Registries states.
    Zhang L; King J; Wu XC; Hsieh MC; Chen VW; Yu Q; Fontham E; Loch M; Pollack LA; Ferguson T
    Cancer Epidemiol; 2019 Feb; 58():1-7. PubMed ID: 30415099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
    Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
    Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
    Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
    J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The distribution of reproductive risk factors disclosed the heterogeneity of receptor-defined breast cancer subtypes among Tanzanian women.
    Rweyemamu LP; Akan G; Adolf IC; Magorosa EP; Mosha IJ; Dharsee N; Namkinga LA; Lyantagaye SL; Nateri AS; Atalar F
    BMC Womens Health; 2021 Dec; 21(1):423. PubMed ID: 34930226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
    Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
    Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies.
    Lambertini M; Santoro L; Del Mastro L; Nguyen B; Livraghi L; Ugolini D; Peccatori FA; Azim HA
    Cancer Treat Rev; 2016 Sep; 49():65-76. PubMed ID: 27529149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population.
    Abubakar M; Sung H; Bcr D; Guida J; Tang TS; Pfeiffer RM; Yang XR
    Breast Cancer Res; 2018 Sep; 20(1):114. PubMed ID: 30227867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of established risk factors with breast cancer subtypes.
    McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
    Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occurrence of breast cancer subtypes in adolescent and young adult women.
    Keegan TH; DeRouen MC; Press DJ; Kurian AW; Clarke CA
    Breast Cancer Res; 2012 Mar; 14(2):R55. PubMed ID: 22452927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in Breast Cancer Survival by Molecular Subtypes in the United States.
    Howlader N; Cronin KA; Kurian AW; Andridge R
    Cancer Epidemiol Biomarkers Prev; 2018 Jun; 27(6):619-626. PubMed ID: 29593010
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of molecular subtype and race on HR+, HER2- breast cancer survival.
    Reid S; Haddad D; Tezak A; Weidner A; Wang X; Mautz B; Moore J; Cadiz S; Zhu Y; Zheng W; Mayer IA; Shu XO; Pal T
    Breast Cancer Res Treat; 2021 Oct; 189(3):845-852. PubMed ID: 34331630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.